On October 16, 2025, Oragenics, Inc. settled a claim for $700,000 with Ladenburg Thalmann & Co. and received notice on October 20, 2025, that it regained compliance with NYSE listing standards, reflecting stockholder equity exceeding $6 million. This follows a public offering in July 2025 that raised approximately $16.5 million.